Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma (Q47861254)

6 February 2018

title

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma (English)

1 reference

6 February 2018

1 reference

6

W Boogerd

0 references

Christian U Blank

3

object named as

C U Blank

1 reference

6 February 2018

author name string

M H Geukes Foppen

1

1 reference

6 February 2018

D Brandsma

2

1 reference

6 February 2018

J V van Thienen

4

1 reference

6 February 2018

J B Haanen

5

1 reference

6 February 2018

W Boogerd

6

1 reference

6 February 2018

publication date

8 March 2016

1 reference

6 February 2018

published in

Annals of Oncology

1 reference

6 February 2018

volume

27

1 reference

6 February 2018

issue

6

1 reference

6 February 2018

page(s)

1138-1142

1 reference

6 February 2018

Leptomeningeal metastases from solid malignancy: a review

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Prognostic factors and outcomes in patients with leptomeningeal melanomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW134

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW134

1 reference

6 February 2018

1 reference

6 February 2018